Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Trial Profile

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Ingenol disoxate (Primary)
  • Indications Actinic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 01 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 04 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 12 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top